The Johns Hopkins University

Surmodics, Inc.

Atherogenics, Inc.

Signe Erickson Varner

Eugene De Juan

Terry Harrison Shelley

Laurie Lawin

Aaron Christopher Barnes

Ralph A Chappa

Aron B Anderson

Eugene Dejuan

Michael J Cooney

Byron C Shen

Mark Salman Humayun

Eugene De Juan, Jr

Charles A Kunsch

Eugene deJuan

Jayraz Luchoomun

Nathan Robert Fox Beeley

Xilin Chen

Eugene Jr De Juan

A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Reservoir device for intraocular drug delivery

Featured is a method for instilling one or more bioactive agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising concurrently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a sustained release delivery device comprising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more bioactive agents subretinally; and (C) instilling (e.g., injecting or delivering by ocular iontophoresis) one or more bioactive agents into the vitreous humor of the eye.

Methods and devices for the treatment of ocular conditions

The invention provides a controlled release bioactive agent delivery device for treatment of an eye that includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, and a polymeric coated composition in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The first polymer and the second polymer are hydrophobic, and the body member has a length such that, upon placement of the device at an implantation site within a posterior segment of an eye, the device does not enter a central visual field of the eye. The invention also provides methods method of delivering bioactive agent to a posterior region of an eye.

Controlled release bioactive agent delivery device

The invention provides a controlled release bioactive agent delivery device that includes a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension, and a polymeric coated composition in contact with the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent, wherein the first polymer comprises polyalkyl(meth)acrylate, aromatic poly(meth)acrylate, or a combination of polyalkyl(meth)acrylate and aromatic poly(meth)acrylate, and wherein the second polymer comprises poly(ethylene-co-vinyl acetate). The invention also provides methods of delivering a bioactive agent to a patient in a controlled release manner, as well as methods of making a controlled release bioactive agent delivery device.

The invention relates to sustained release implants and to methods for treating eyes, particularly the eyes of mammals having eye disorders or diseases. By using the implants and methods described herein, the delivery of the one or more bioactive agents can be localized at a desired treatment site, particularly the choroid and the retina.

Sustained release implants and methods for subretinal delivery of bioactive agents to treat or prevent retinal disease

The invention provides implantable sustained release bioactive agent delivery devices that include a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension; and a polymeric coated composition in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent. The polymeric coated composition is formulated to provide controlled release of bioactive agent over time when introduced into physiological conditions. Methods of preparing implantable devices configured and formulated to provide controlled release of bioactive agent are also provided.

The invention provides retrievable devices for sustained delivery of bioactive agent to a site within a patient, the devices including a body member having a direction of extension, a longitudinal axis along the direction of extension, and a proximal end and a distal end, wherein at least a portion of the body member deviates from the direction of extension; a cap at the proximal end of the body member; and a polymeric coated composition in contact with a surface of the body member, the polymeric coated composition including a first polymer, a second polymer, and a bioactive agent.

Devices and devices for the treatment of the eye are disclosed. Preferred devices of the invention include a piercing member that is inserted into the eye to create a pathway for a cannula. The cannula is slidably mounted to the piercing member and is adapted to reach a treatment site within the eye at which material is injected into and/or withdrawn from the eye. The outer diameter of the piercing member is small enough to allow for self-sealing of the insertion site of the device upon the device's withdrawal therefrom. Also disclosed are methods for the utilizing the devices to treat the eye.

Method for drug delivery through the vitreous humor

This invention is in the area of regulatory DNA sequences and their methods of use. Specifically, DNA sequences found in the regulatory region of cytoprotective genes are described that are termed cytoprotective response elements. DNA constructs also are provided that include cytoprotective response elements operably linked to heterologous protein coding sequence, as well as cells and non-human organisms that include the cytoprotective response elements optionally operably linked to a heterologous protein coding sequence, and a method for screening for a compound that increases mRNA or protein regulated by a cytoprotective response element. It has been discovered that the cytoprotective response elements mediate the coordinate activation of certain genes that protect cells from damaging effects of oxidative stress, and that they do so, for example during conditions of hemodynamic shear stress.

Protection against oxidative stress and inflammation by a cytoprotective response element

An therapeutic agent delivery device that can allows is particularly suitable for delivery of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. Preferred devices of the invention are minimally invasive, refillable and may be easily fixed to the treatment area. Preferred delivery devices of the invention also include those that comprise a non-linear shaped body member body housing one or more substances and a delivery mechanism for the sustained delivery of the one or more substances from the non-linear shaped body member to the patient.

Growing community of inventors

Los Angeles, CA, United States of America

Signe Erickson Varner